douglas
improving lives

Douglas Pharmaceuticals Limited

Your Trusted Partner

- Pharmaceutical product out-licensing
- In-licensing
- Co-development
- Contract manufacturing and development services



NEW ZEALAND.COM
Licence No.101032

Introducing Douglas Pharmaceuticals

Douglas is a family-owned pharmaceutical company with a reputation for high manufacturing standards, quality products and outstanding client service.

Douglas' talented team collaborates with a network of innovative partners to meticulously research, develop, manufacture, market, and distribute life-changing pharmaceutical products to more than 90 countries worldwide.

Every product we create is a testament to our commitment to quality, developed in full compliance with the highest international standards and regulatory authorities.

Douglas' pharmaceutical capabilities include the making of solid oral dose formulations (tablets and capsules) and a variety of liquid, oral and topical formulations (softgel capsules, solutions, suspensions, creams, lotions and gels).

Manufacturing

Douglas products are made to international standards known as GMP (Good Manufacturing Practice). Our manufacturing facilities undergo regular inspections by both local and international authorities, including Medsafe and the US FDA.

These inspections confirm Douglas' ongoing compliance and provide independent assurance that systems, facilities, and processes consistently meet the high standards expected of modern pharmaceutical manufacturing.

Douglas is certified to Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good Manufacturing Practice for Medicine by New Zealand's health authority, Medsafe. This allows Douglas to supply to most PIC/S authorities without further need for GMP inspection.

Our Medsafe certification is recognised under the mutual recognition agreement (MRA) with European countries and the UK, allowing Douglas to supply to EU and UK without retesting or further need for GMP inspection.

Recent inspections

Medsafe New Zealand	**2024**
US FDA	**2025**

Quality assurance

Quality is a core principle at Douglas and a defining element of how the company operates. Every employee plays an active role in maintaining and improving quality, ensuring that the organisation remains a trusted and reliable partner in the development and supply of medicines.

In 2024, Douglas was one of only nine companies selected globally to participate in the US FDA's Quality Management Maturity Pilot Study. This is an ongoing, in-depth review of our processes that contribute to our ability to deliver the right quality products on time.

A New Zealand success story

Douglas was founded in 1967 by West Auckland chemist Sir Graeme Douglas. He dispensed prescription medicines from his pharmacy in Te Atatu, until seeing a need for a cough syrup amongst his own customers and formulating a product he called Kofsin.

In 1980 he turned his hand to manufacturing and by the 1990s he was successfully researching and developing his own products for the domestic and international markets.

In 2014, Sir Graeme's son Jeff Douglas took over as Managing Director, and from 2026 is Executive Director on the Douglas Board. Today Douglas is New Zealand's largest healthcare company, with over 500 staff.



Jeff Douglas and Sir Graeme Douglas

Opportunities

Global out-licensing

Douglas has over 55 years of manufacturing experience in commercialised pharmaceuticals, specialising in generics and branded generics. These continue to be marketed around the world in over 90 countries. We are interested in hearing from companies wanting to license our generic and branded generic pharmaceuticals for their region.

See our international product range on pages 6-7.

New Zealand and Australia

Douglas is actively seeking promising in-licensing opportunities for New Zealand and Australia.

With a long history and a robust supply chain, we offer what few partners can – a base of operations in both Australia and New Zealand. We are interested in novel compounds, innovative drug delivery systems, and established products across a wide range of therapeutic areas.

If you have a compelling asset that aligns with our strategic objectives, we encourage you to connect with us.

See our in-licensing target list on pages 8-9.

Partnering with Douglas

Douglas offers a comprehensive range of services to our partners for both the New Zealand and Australian markets. These include:

- **Market access:** Utilise our established distribution network and in-depth local market intelligence to ensure a successful product launch and sustained management.
- **Regulatory efficiency:** Benefit from our proven track record in navigating New Zealand and Australia's regulatory requirements and managing the full product lifecycle in compliance with government standards.
- **Pharmacovigilance:** Assistance for compliance maintenance and expert support for pharmacovigilance and quality audits.
- **Legal support:** Available for diligence and strategic advice.
- **Experienced commercial team:** Utilise our sophisticated systems for pricing, forecasting, inventory optimisation and tendering.
- **Sales support:** Douglas has highly experienced marketing and sales resources across Australia and New Zealand.
- **Reliability:** Partner with an organisation known for its long-standing quality, ethical conduct, and financial stability in the region.
- **Sustainability:** Align with a partner dedicated to responsible manufacturing, ethical supply chains, and measurable Environmental, Social, and Governance (ESG) standards.

Douglas Australia

Douglas has manufactured and supplied pharmaceutical products to Australia for over a quarter of a century, supplying essential medicines including isotretinoin, acitretin and clozapine. Our Australian office is situated in Melbourne, where our team are on hand to provide support and education.

Douglas Australia is actively seeking to expand its portfolio through strategic collaboration with international and domestic pharmaceutical enterprises. We invite companies seeking to introduce their products to the Australian market to leverage our established platform.



International reach



New Zealand and international recognition

WINNER 2025 MANUFACTURER OF THE YEAR

New Zealand Manufacturer of the Year 2025.

TOITŪ CARBON REDUCE ISO 14064-1 ORGANISATION 5 YEARS

Achieved 25% CO2 emission reduction over 5 years with Toitū, New Zealand's leading carbon reduction program.

douglas
improving lives



SiteWise Green in workplace health and safety.

2025 Global Top 100 Inspiring Workplaces. Ranked second in Australasia, 35th globally.

EcoVadis Commitment Badge 2026

Product range

Acitretin



Strength:
10 mg, 17.5 mg, 22.5 mg, 25 mg
Form: Capsules
Dossier available: Yes
Branded generic available:
Novatretin™

Dermatology

Alitretinoin



Strength: 10 mg, 30 mg
Form: Softgel capsules
Dossier available: Yes
Branded generic available:
Zematane™

Dermatology

Isotretinoin



Strength:
5 mg, 10 mg, 20 mg, 30 mg, 40 mg
Form: Softgel capsules
Dossier available: Yes
Branded generic available: Oratane™

Dermatology

Azathioprine



Strength:
25 mg, 50 mg, 75 mg and 100 mg
Form: Tablets
Dossier available: Yes
Branded generic available: Azamun™

Immunology

Cyproterone Acetate



Strength: 50 mg, 100 mg
Form: Tablets
Dossier available: Yes

Endocrinology

Ethinylestradiol and Cyproterone Acetate



Strength: 35 mcg/2 mg
Form: Tablets
Dossier available: Yes
Branded generic available: Estelle™

Endocrinology

Posaconazole Oral Suspension



Strength: 40 mg/m
Form: Oral suspension
Dossier available: Yes

Anti-infective

Ketoconazole



Strength: 2%
Form: Shampoo
Dossier available: Yes
Branded generic available: Sebizole™

Anti-fungal

Bexarotene



Strength: 75 mg
Form: Softgel capsules
Dossier available: Yes

Oncology

Clozapine



Strength:
25 mg, 50 mg, 100 mg, 200 mg
Form: Tablets
Dossier available: Yes
Branded generic available: Clopine™

Central Nervous System/Psychiatry

Clozapine Suspension



Strength: 50 mg/ml
Form: Oral suspension
Dossier available: Yes
Branded generic available: Versacloz™

Central Nervous System/Psychiatry

Methylphenidate



Strength: 10 mg
Form: Tablets
Dossier available: Yes

Central Nervous System/Psychiatry

Paricalcitol



Strength: 1 mcg, 2 mcg
Form: Softgel capsules
Dossier available: Yes

Endocrinology

Information correct as of February 2026. For detailed technical specifications, regulatory dossiers, prescribing information (PI), manufacturing process data, and confidential commercial terms, please visit douglas.co.nz or email info@douglas.co.nz

Please note all images are indicative only. Not real product.



In-licensing opportunities

Products of interest for the New Zealand and Australian markets

Douglas is committed to building long-term partnerships through strategic in-licensing.

By collaborating with global partners, we bring high quality medicines to New Zealand and Australia, delivering value to patients and healthcare systems where there is unmet need.



ATC	MOLECULE	STRENGTHS AND DOSAGE FORMS
Alimentary Tract and Metabolism	Mesalazine	400 mg, 800 mg, 1.6 g Tablets 500 mg Modified Release Tablets 500 mg and 1 g Suppositories 1 g Modified Release Granules 1 g/ 100 mL Enema Bottle
Alimentary Tract and Metabolism	Rifaximin	200 mg and 500 mg Tablets 550 mg Tablets
Alimentary Tract and Metabolism	Sapropterin	100 mg Soluble Tablets 100 mg and 500 mg Oral Powder Sachets
Antiinfectives for Systemic Use	Raltegravir potassium	Tablets 400 mg and 600 mg
Antiinfectives for Systemic Use	Amphotericin B	Liposomal Injection 50 mg
Antineoplastic and Immunomodulating Agents	Tofacitinib	5 mg and 10 mg Tablets 1 mg/mL Oral Liquid
Antineoplastic and Immunomodulating Agents	Ruxolitinib	5 mg, 10 mg, 15 mg, 20 mg Tablets 1.5% Topical Cream
Antineoplastic and Immunomodulating Agents	Palbociclib	75 mg, 100 mg, 125 mg Tablets
Antineoplastic and Immunomodulating Agents	Ocrelizumab	920 mg/23 mL Injection 300 mg/10 mL Injection
Antineoplastic and Immunomodulating Agents	Lenalidomide	5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsules
Antineoplastic and Immunomodulating Agents	Apremilast	10 mg, 20 mg, 3 0mg Tablets
Antineoplastic and Immunomodulating Agents	Leuproreline Acetate	3.75 mg, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg Modified Release Injections
Blood and Blood Forming Organs	Icatibant	10 mg per ml, 3 ml Prefilled Syringe Injections
Blood and Blood Forming Organs	Iron	Iron (as ferric carboxymaltose) 50 mg per ml, 10 ml Vial Injections
Blood and Blood Forming Organs	Tecnecteplase	50 mg Injection Vials
Cardiovascular System	Macitentan	10 mg Tablets

ATC	MOLECULE	STRENGTHS AND DOSAGE FORMS
Cardiovascular System	Guanfacine	1 mg, 2 mg, 3 mg, and 4 mg Modified Release Tablets
Dermatologicals	Dupilumab	200 mg/1.14 mL Injection 300 mg/2 mL Injection, Syringes and Pen Devices
Genito Urinary System and Sex Hormones	Oestradiol	25 mcg, 50 mcg, 75 mcg, and 100 mcg per day TDDS
Genito Urinary System and Sex Hormones	Oestriol	1 mg per g Cream with Applicator(s)
Hormone Preparations - Systemic Excluding Contraceptive Hormones	Goserelin	3.6 mg and 10.8 mg, Syringe Implant
Musculo-Skeletal System	Denosumab	120 mg/mL Injection 120 mg/1.7 mL Injection 60 mg/mL Injection
Musculo-Skeletal System	Botulinum Toxin	50 U, 100 U and 200 U Injection Vial
Nervous System	Orphenadrine Citrate	100 mg Tablets
Nervous System	Aripiprazole	300 mg and 400 mg Modified Release Injection Vials 720 mg/2.4 mL Modified Release Injection Syringe 960 mg/3.2 mL Modified Release Injection Syringe
Nervous System	Paliperidone	25 mg, 50 mg, 75 mg, 100 mg, 150 mg Modified Release Injection Syringe 175 mg/0.875 mL Modified Release Injection 263 mg/1.315 mL Modified Release Injection 350 mg/1.75 mL Modified Release Injection 525 mg/2.625 mL Modified Release Injection 700 mg/3.5 mL modified release injection
Nervous System	Risperidone	25mg, 37.5mg, 50mg, 75mg, 100mg modified release Injection vials
Nervous System	Lisdexamfetamine	20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg Capsules
Nervous System	Methylphenidate	10 mg, 20 mg, 30 mg, 40 mg, 60 mg Modified Release Capsules 18 mg, 27 mg, 36 mg, 54 mg Modified Release Tablets
Respiratory System	Omalizumab	75 mg/0.5 mL Injection 150 mg/mL Injection 300 mg/2 mL Injection



Generic Drug Development

Co-development product opportunities

Douglas specialises in complex generic product developments that have technical, clinical or IP complexity.

Douglas has a robust portfolio of innovative projects in various therapeutic areas and is seeking co-development partners with complementary expertise and resources to accelerate the development and commercialisation of these promising therapies.

Complex Generic Pipeline

MOLECULE	FORM	INDICATION	ESTIMATED LAUNCH
Testosterone undecanoate	Soft-gel capsule	Hormone replacement therapy	2031
Tafamidis meglumine	Soft-gel capsule	ATTR polyneuropathy	2029
Tafamidis	Soft-gel capsule	ATTR polyneuropathy	TBC
Adapalene; Benzoyl Peroxide; Clindamycin	Topical gel	Acne vulgaris	TBC
Talazoparib	Soft-gel capsule	Prostate cancer and breast cancer	TBC

Why partner with Douglas?

- **Strong technical capability:** With over 58 years of experience in pharmaceutical development, manufacturing, and commercialisation, we possess the knowledge and insights to navigate the complexities of the healthcare landscape. Douglas is world-renowned for its softgel formulation, microdosage capabilities and high potency formulations.
- **State of the art facilities:** Our GMP-certified manufacturing plant, advanced research laboratories, and access to clinical research trial teams provide the infrastructure necessary to support projects from concept to commercialisation.
- **Commitment to quality:** Douglas is renowned for adherence to the highest international quality standards, ensuring the safety and efficacy of all our products.
- **Flexible partnership models:** We understand that every project is unique. We offer flexible partnership models tailored to your needs and objectives.



To learn more, please contact:
Lisa Craigie, Chief Commercial Officer,
lisac@douglas.co.nz


douglas
improving lives

Our facilities in Auckland, New Zealand

Douglas Innovation Centre



Douglas Corporate Office





Production plant	3900 m^2
NPD labs	930 m^2
Analytical labs	930 m^2
Warehouse and distribution	3,716 m^2
Offices	3,160 m^2

Douglas Manufacturing



12,600 m^2 of modern facilities



Over 500 employees





Douglas CDMO

Specialised manufacturing for US and EU market entry

Douglas CDMO supports pharmaceutical companies progressing their products into the US, EU, and UK markets.

We operate an FDA-approved, internationally recognised manufacturing facility, partnering closely with clients to support efficient scale-up and reliable commercial supply into these regions.

Highly experienced in softgel and liquid dosage forms

Our facility and teams are highly specialised in softgel and liquid formulations, including high-potency products and complex molecules.

With operations dating back to 1967, Douglas has extensive experience delivering technology transfers, scale-up, and commercial manufacture, with established controls for light-sensitive retinoids, hormones, cytotoxics, and immunosuppressants.

Projects are managed by stable, experienced teams with direct access to senior technical and quality leadership. Our teams focus on consistency, speed, and clear decision-making and operate comfortably across regions and regulatory systems.

Our Asia–Pacific location provides close time-zone alignment with China, supporting responsive communication and collaboration.

Product capabilities

Alongside our proven expertise in softgel and liquid formulations, Douglas offers manufacturing capabilities across a wider range of dosage forms.



Softgel capsules



Liquids, including solutions, emulsions and suspensions



Semi-solids, including creams, gels and ointments



Hard gel capsules



Suppositories



Tablets, coated and uncoated

A framework for international commercialisation

Direct US market access

Manufacture your products in our FDA-approved facility, removing key regulatory barriers to US commercialisation.

Access to EU, UK, and PIC/S markets

Douglas is certified to the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to GMP by New Zealand's health authority, Medsafe. As a result, GMP inspections conducted by Medsafe are recognised by other PIC/S member authorities, enabling supply to multiple EU, UK, and PIC/S markets without the need for additional GMP inspections.

Proven technology transfer expertise

We have a strong track record of successful technology transfer projects, partnering closely with clients to ensure efficient, compliant scale-up and reliable commercial supply.

Recognised for our commitment to quality

In 2024, Douglas was selected as one of only nine companies worldwide to participate in the FDA's Quality Management Maturity (QMM) Pilot Program. This involved a rigorous assessment of operational excellence, quality culture, and supply reliability.

Regulatory confidence

Successfully audited by Medsafe, New Zealand's regulatory body, and the U.S. FDA within the past five years.

Talk to Douglas CDMO about your next project for a collaborative and successful partnership.

NEW ZEALAND.COM
Licence No.101032



Recognition and awards

New Zealand Manufacturer of the Year 2025

EcoVadis Bronze Sustainability Rating

#2 Most inspiring Workplace across New Zealand and Australia by the Inspiring Workplace Awards 2025

SiteWise Green in Workplace Health and Safety

Achieved 25% CO2 emission reduction over 5 years with Toitū, New Zealand's leading carbon reduction program.

douglas
improving lives

Douglas Pharmaceuticals Ltd
2 Te Pai Pl, Henderson,
Auckland 0610,
New Zealand
Phone: +64 9 835 0660
www.douglas.co.nz